IFNA1 and Sjogren syndrome: Due to its substantial advantages when compared to monoclonal Abs (absence of anti-drug Abs formation, neutralization of all IFNα subtypes (56), better predictable patient compliance because of a low number of administrations (21), lower production and health care costs...) and its good safety profile (20, 21), IFN-K is the good candidate for Sjögren’s syndrome’s treatment, but of course, further studies are required to confirm this proof-of-concept.